Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
The use of OKT3 as an immunosuppressive agent is accompanied by increased cytokine production and constellation of side effects collectively termed cytokine release syndrome (CRS). Pentoxifylline (PTF) inhibits synthesis of some cytokines, and has been shown to attenuate CRS when administered before OKT3. In this double-blinded, placebo-controlled study, 46 renal allograft recipients were randomized to receive either PTF (800 mg q 8 hr for at least 24 h) p.o. or placebo, along with methylprednisolone (7 mg/kg), diphenhydramine, and acetaminophen, prior to beginning OKT3 as therapy for acute rejection. Patients were observed, and symptoms scored semiquantitatively. Despite the presence of therapeutic PTF levels (721 +/- 726 ng/ml), the frequency and severity of side effects (fever, chills, headache, neurocortical symptoms, dyspnea, nausea, vomiting, diarrhea) did not differ between treatment groups. Likewise PTF did not affect renal function or immunologic response to OKT3, with similar graft and patient survival in both groups. Plasma levels of TNF alpha, IFN gamma, IL-6, and IL-8 increased as predicted following OKT3 administration, without significant differences between PTF and placebo groups. In this controlled, multicenter trial, pretreatment with oral PTF was ineffective in attenuating OKT3-related CRS in renal allograft recipients.
Vincenti
F
F
University of California, San Francisco, 94143, USA.
Danovitch
G M
GM
Neylan
J F
JF
Steiner
R W
RW
Everson
M P
MP
Gaston
R S
RS
D000328:Adult; D000818:Animals; D017252:CD3 Complex / Q000097:blood; D016207:Cytokines / Q000096:biosynthesis* / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007371:Interferon-gamma / Q000097:blood; D007668:Kidney / Q000276:immunology / Q000502:physiology; D016030:Kidney Transplantation / Q000276:immunology; D018655:Lymphocyte Count / Q000187:drug effects; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D051379:Mice; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D010431:Pentoxifylline / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D017252:CD3 Complex; D016207:Cytokines; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D010431:Pentoxifylline